List of Excipients in Branded Drug RESTASIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	RESTASIS	cyclosporine	0023-9163	CARBOMER COPOLYMER TYPE A
Allergan Inc	RESTASIS	cyclosporine	0023-9163	CASTOR OIL
Allergan Inc	RESTASIS	cyclosporine	0023-9163	GLYCERIN
Allergan Inc	RESTASIS	cyclosporine	0023-9163	POLYSORBATE 80
Allergan Inc	RESTASIS	cyclosporine	0023-9163	SODIUM HYDROXIDE
Allergan Inc	RESTASIS	cyclosporine	0023-9163	WATER

Restasis Excipient Strategy and Commercial Opportunities in Cyclosporine Ophthalmic Emulsions

Last updated: September 7, 2026

Restasis is a preservative-free, topical cyclosporine ophthalmic emulsion containing 0.05% cyclosporine. Its commercial differentiation depends less on the active ingredient than on emulsion stability, ocular tolerability, delivery-device performance, unit-dose packaging, and manufacturing consistency. The largest opportunities are generic and branded-generic substitution, multidose preservative-free delivery, improved comfort, higher-concentration cyclosporine, and differentiated formulations for dry-eye patients who do not respond adequately to existing products.

What excipients are used in Restasis?

Restasis contains cyclosporine 0.05% as the active pharmaceutical ingredient. The labeled inactive ingredients are glycerin, castor oil, polysorbate 80, carbomer copolymer Type A, purified water, and sodium hydroxide for pH adjustment.[1]

Component	Functional role	Commercial relevance
Cyclosporine	Immunomodulatory active ingredient	Poorly water-soluble; requires dispersed or emulsified delivery
Castor oil	Lipid phase and solvent for cyclosporine	Supports drug solubilization and emulsion structure
Polysorbate 80	Surfactant and emulsifier	Controls droplet formation and physical stability
Carbomer copolymer Type A	Rheology modifier and stabilizer	Supports residence time and emulsion stability
Glycerin	Humectant and tonicity contributor	Influences comfort and ocular surface hydration
Purified water	Continuous aqueous phase	Controls dispersion and product uniformity
Sodium hydroxide	pH adjustment	Affects tolerability, viscosity, and emulsion behavior

The formulation is an oil-in-water emulsion. Cyclosporine is incorporated into the oil phase, while the surfactant and polymer stabilize dispersed droplets in the aqueous phase. This approach avoids the poor aqueous solubility of cyclosporine and permits topical delivery to the ocular surface.

Why does the Restasis excipient system matter commercially?

The excipient system determines whether a competitor can reproduce the reference product’s performance without copying its exact composition. Generic approval requires pharmaceutical equivalence and bioequivalence under the applicable FDA pathway, but complex ophthalmic emulsions create additional development risks.

Key performance attributes include:

• Cyclosporine concentration and assay uniformity
• Droplet-size distribution
• Emulsion viscosity
• Redispersibility after storage
• Surface tension and spreading
• pH and osmolality
• Container-closure compatibility
• Sterility throughout shelf life
• Extractables and leachables
• Ocular irritation and tolerability
• Delivered dose from the vial or multidose device

A formulation can match the nominal cyclosporine concentration but differ in droplet size, viscosity, surface activity, or delivered dose. Those differences can affect patient comfort, retention on the eye, and manufacturing reproducibility.

The principal commercial barrier is therefore not simply sourcing the listed excipients. It is reproducing the finished-product microstructure and performance profile at industrial scale.

What formulation risks arise from the Restasis excipients?

Cyclosporine solubility and precipitation

Cyclosporine is highly lipophilic and has limited water solubility. The castor-oil phase must maintain drug solubilization during manufacturing, storage, temperature cycling, and use. Precipitation can reduce dose uniformity and increase particulate risk.

Potential development controls include:

• Oil-phase composition
• Mixing energy and homogenization
• Surfactant-to-oil ratio
• Temperature during processing
• Order of ingredient addition
• Holding time before filling
• Freeze-thaw and accelerated stability testing

Surfactant tolerability

Polysorbate 80 supports emulsion formation but can contribute to ocular discomfort or irritation at inappropriate concentrations. Its level must balance physical stability with patient acceptance.

Changes in surfactant grade, peroxide content, or impurity profile can affect both stability and tolerability. Suppliers with ophthalmic-grade documentation and strong control of oxidative impurities have a commercial advantage.

Carbomer behavior

Carbomer copolymer Type A controls viscosity and contributes to physical stability. Excessive viscosity can impair drop formation, blur vision, or reduce patient adherence. Insufficient viscosity can reduce residence time and allow rapid drainage.

Carbomer performance depends on neutralization, pH, ionic strength, mixing conditions, and polymer lot characteristics. Small process changes can produce meaningful differences in viscosity and rheology.

Glycerin and ocular comfort

Glycerin contributes to tonicity and humectancy. Its concentration affects osmotic balance and comfort. A formulation that is chemically stable but causes stinging or transient blur can lose market share in a chronic-use indication.

What delivery formats are protected by the Restasis strategy?

Restasis has been commercialized primarily in preservative-free unit-dose vials and a multidose presentation. The dosage form is typically administered as one drop in each affected eye twice daily, approximately 12 hours apart.[1]

Format	Commercial benefit	Development challenge
Single-use vial	Strong preservative-free positioning; simple sterile package	Higher packaging cost and waste
Multidose bottle	Lower per-dose packaging cost; better convenience	Maintaining sterility after repeated use
Pump or metered-dose device	Controlled dose and reduced contamination exposure	Device complexity and combination-product requirements
Gel or in situ gelling system	Potentially longer residence time	Blur, drop-force, and tolerability risks
Liposomal or nanoemulsion system	Potentially improved delivery or comfort	Scale-up, characterization, and regulatory complexity

The multidose opportunity is substantial because it addresses the cost and environmental disadvantages of unit-dose packaging. It also creates device-related intellectual-property opportunities involving dispensing geometry, contamination control, dose metering, and residual-volume reduction.

What patents protect Restasis and its generic competition?

Restasis patent protection has historically included claims directed to cyclosporine ophthalmic emulsions, topical delivery, formulation components, and related manufacturing or packaging features. The original composition and method-of-use protections have largely expired or lost practical exclusivity, while later formulation and device patents have had more limited remaining commercial value.

The FDA Orange Book is the controlling public source for patents listed against approved Restasis products and should be reviewed by product presentation and current listing status.[2] Patent exposure has included:

• Composition-of-matter or formulation claims
• Oil-in-water ophthalmic emulsions
• Cyclosporine concentration and dosing
• Methods for treating keratoconjunctivitis sicca
• Multidose delivery systems
• Container-closure and dispensing arrangements

Patent risk is presentation-specific. A generic seeking approval for a single-use vial may face a different patent profile from a company developing a multidose bottle or a higher-concentration formulation.

Paragraph IV and litigation exposure

Restasis generic competition generated extensive Paragraph IV activity and litigation involving formulation patents. Generic applicants challenged listed patents while asserting invalidity, non-infringement, or unenforceability. Allergan also faced scrutiny over its effort to transfer Restasis patents to the Saint Regis Mohawk Tribe, a strategy intended to invoke tribal sovereign immunity. The Federal Circuit rejected the immunity argument in 2018, and the Patent Trial and Appeal Board continued the relevant inter partes review proceedings.[3][4]

The litigation reduced the ability of later Restasis patents to delay generic entry. It also established a practical lesson for ophthalmic products: patents directed to predictable excipient combinations or routine formulation optimization face greater vulnerability than patents supported by unexpected performance data.

When did Restasis lose exclusivity?

Restasis received FDA approval in 2003 for increasing tear production in patients whose tear production is suppressed because of ocular inflammation associated with keratoconjunctivitis sicca.[1] Its five-year new-chemical-entity exclusivity period ended in 2008, subject to the applicable pediatric-exclusivity calculation.

The product’s commercial exclusivity then depended primarily on patents and regulatory barriers. FDA-approved generic cyclosporine ophthalmic emulsions began reaching the U.S. market in 2022, materially reducing the exclusivity value of the original Restasis formulation.[5]

Milestone	Date or status
FDA approval of Restasis	2003
Five-year NCE exclusivity	Expired in the late 2000s
Multidose Restasis approval	2016
Major generic approvals	Began in 2022
Current market structure	Brand, authorized or branded-generic products, and generic cyclosporine emulsions

What FDA regulatory pathway applies to generic cyclosporine ophthalmic emulsion?

Cyclosporine ophthalmic emulsion is a small-molecule drug, not a biologic. Biosimilar approval under the Public Health Service Act does not apply. Generic competitors generally pursue an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

For complex ophthalmic emulsions, the principal technical issue is establishing equivalence to the reference listed drug. FDA guidance and product-specific expectations can require comparative characterization beyond simple chemical assay. Relevant evidence may include:

• Active-ingredient identity and strength
• Excipient composition
• Emulsion droplet-size distribution
• Rheological properties
• Surface tension
• Osmolality and pH
• Microbial quality
• Sterility assurance
• In vitro release or performance testing
• Comparative clinical or pharmacodynamic evidence where required

A competitor may use different excipient grades or manufacturing equipment, but the finished product must meet applicable equivalence and quality requirements. A materially different excipient system can create regulatory, clinical, and patent complications.

What commercial opportunities exist for Restasis excipients?

1. Preservative-free multidose systems

The strongest near-term opportunity is a reliable preservative-free multidose device. The product must prevent microbial ingress while delivering consistent drops over the labeled in-use period.

Value drivers include:

• Lower packaging cost than 60 individual vials
• Reduced patient handling burden
• Improved adherence
• Lower shipping volume
• Differentiation from standard generic vials

A company that combines a stable cyclosporine emulsion with a validated multidose dispenser can compete on convenience rather than price alone.

2. Improved comfort formulations

Stinging and transient blurred vision are common barriers in chronic dry-eye treatment. Excipient optimization could target:

• Lower surfactant burden
• Tonicity closer to natural tears
• Reduced viscosity immediately after instillation
• More rapid spreading
• Lower oil-phase irritation
• Reduced drop volume

The formulation must preserve cyclosporine stability while improving patient experience. Clinical tolerability data can support premium positioning and payer differentiation.

3. Higher-concentration cyclosporine

A 0.1% or other higher-concentration product could target patients with inadequate response to 0.05% therapy. The commercial opportunity depends on demonstrating clinically meaningful benefit without materially increasing irritation, blur, or manufacturing cost.

Higher concentration creates formulation pressure because more cyclosporine must remain solubilized in the oil phase. It may require changes in oil content, surfactant ratio, viscosity, and dose volume. Those changes can create new patentable subject matter if supported by unexpected stability or clinical results.

4. Alternative lipid systems

Castor oil is effective but not the only potential lipid vehicle. Competitors may evaluate medium-chain triglycerides, synthetic lipids, phospholipid systems, or mixed oil phases.

A replacement lipid should be assessed for:

• Cyclosporine solubilization capacity
• Oxidative stability
• Ocular tolerance
• Emulsion droplet size
• Compatibility with surfactants
• Sterilization and filling behavior
• Supplier security and cost

The commercial benefit is strongest where a new lipid system materially improves comfort, stability, or manufacturing yield.

5. Combination products

Cyclosporine could be paired with lubricants, osmoprotectants, anti-inflammatory agents, or other ocular-surface therapies. Combination products create potential differentiation but also increase regulatory complexity and may introduce new safety and patent issues.

6. Excipient supply and contract manufacturing

Specialty suppliers can capture value by providing:

• Ophthalmic-grade castor oil
• Low-peroxide polysorbate 80
• Controlled-rheology carbomer
• Sterile or low-bioburden excipient systems
• Ready-to-use emulsion concentrates
• Validated filling and aseptic-processing services

Manufacturing know-how can become a barrier when it improves batch-to-batch droplet-size control, reduces residual volume, or increases sterile filling yield.

How strong is the Restasis patent estate today?

The original Restasis franchise has limited ability to block standard generic cyclosporine ophthalmic emulsion competition because core exclusivity periods have expired and FDA-approved generics are commercially available. Remaining value is more likely to reside in:

• Multidose delivery devices
• Specific dispenser architecture
• New concentrations
• Improved excipient ratios
• Combination products
• Manufacturing processes
• Patient-use and adherence innovations

The strongest future patent claims will require narrow technical definition and comparative evidence. Broad claims covering routine use of known ophthalmic excipients are more vulnerable to invalidity challenges.

What generic launch risks exist?

Generic launch risks fall into five categories:

1. Regulatory risk from failure to demonstrate equivalence.
2. CMC risk from unstable emulsions or inconsistent droplet size.
3. Patent risk from listed formulation or device claims.
4. Manufacturing risk from aseptic filling losses and unit-dose packaging cost.
5. Commercial risk from rapid price erosion after multiple generic entrants.

A low-cost vial product can enter quickly but may face weak margins. A multidose product requires more development but can preserve pricing through convenience and reduced waste.

How does Restasis compare with competing dry-eye products?

Product	Active ingredient	Delivery type	Strategic distinction
Restasis	Cyclosporine 0.05%	Ophthalmic emulsion	Established brand and broad clinical familiarity
Xiidra	Lifitegrast 5%	Ophthalmic solution	Different anti-inflammatory mechanism
Cequa	Cyclosporine 0.09%	Nanomicellar solution	Higher concentration and alternative delivery platform
Vevye	Perfluorohexyloctane	Ophthalmic solution	Lipid-layer and evaporative dry-eye positioning
Generic cyclosporine emulsion	Cyclosporine 0.05%	Ophthalmic emulsion	Price competition with reference product

Cequa is the most direct branded formulation competitor because it uses cyclosporine at a higher concentration and a nanomicellar delivery system. Xiidra competes through mechanism and product positioning rather than excipient similarity. Vevye competes for patients with evaporative or lipid-layer dysfunction.

Key Takeaways

• Restasis uses an oil-in-water emulsion built around castor oil, polysorbate 80, carbomer copolymer Type A, glycerin, purified water, and pH adjustment with sodium hydroxide.
• The main technical value lies in controlling cyclosporine solubilization, droplet size, viscosity, sterility, dose uniformity, and ocular comfort.
• Restasis’ original market exclusivity has ended, and FDA-approved generic cyclosporine emulsions entered the U.S. market in 2022.
• Biosimilar risk does not apply because cyclosporine is a small-molecule drug.
• The most attractive commercial opportunities are preservative-free multidose delivery, higher-concentration cyclosporine, improved-comfort formulations, alternative lipid systems, and specialized manufacturing.
• Future patent strength will depend on narrow formulation, device, process, and performance claims supported by comparative data.
• Unit-dose packaging remains a cost and waste disadvantage, while multidose delivery offers a credible product-differentiation strategy.

FAQs

Can a generic Restasis product use different excipients?

Yes. A generic may use different excipients if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and product performance. The formulation must still deliver comparable cyclosporine performance and meet ophthalmic safety requirements.

Is polysorbate 80 essential to every cyclosporine ophthalmic product?

No. Polysorbate 80 is used in Restasis, but alternative surfactants or lipid systems may be possible. Any replacement must maintain emulsion stability, drug uniformity, sterility, and ocular tolerability.

Why is a preservative-free multidose bottle difficult to develop?

The device must prevent microbial contamination during repeated use while delivering a consistent drop volume. The formulation must also remain stable after repeated air exposure, temperature changes, and mechanical dispensing.

Does Restasis have biosimilar competition?

No. Restasis contains cyclosporine, a small-molecule active ingredient. Competition proceeds through generic drug pathways rather than biosimilar approval.

Can a new cyclosporine formulation receive separate patent protection?

Yes. A new formulation, delivery device, concentration, manufacturing process, or combination product may receive patent protection if it satisfies novelty, non-obviousness, written-description, and enablement requirements. Broad claims based only on substituting familiar excipients face higher validity risk.

References

1. U.S. Food and Drug Administration. (2018). Restasis (cyclosporine ophthalmic emulsion) 0.05% prescribing information. Allergan, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Allergan USA, Inc. v. Saint Regis Mohawk Tribe, 896 F.3d 1328 (Fed. Cir. 2018).

4. U.S. Patent and Trademark Office, Patent Trial and Appeal Board. (2018). Mylan Pharmaceuticals Inc. v. Saint Regis Mohawk Tribe and Allergan, Inc., IPR2016-01127 and related proceedings.

5. U.S. Food and Drug Administration. (2022). FDA-approved cyclosporine ophthalmic emulsion products and abbreviated new drug application approvals. FDA Drugs@FDA database.